Table 1 Distribution of KLHL18 status in non-small cell lung cancer according to clinicopathological characteristics
Characteristics | Number of patients | KLHL18 overexpression | KLHL18 negative or weak expression | P-value |
|---|---|---|---|---|
Age | ||||
 ≥ 50 years | 139 | 79 (56.83%) | 60 (43.17%) | 0.245 |
 < 50 years | 75 | 49 (65.33%) | 26 (34.67%) |  |
Sex | ||||
 Male | 110 | 65 (59.10%) | 45 (40.90%) | 0.889 |
 Female | 104 | 63 (60.58%) | 41 (39.42%) |  |
Histology | ||||
 Adenocarcinoma | 113 | 68 (60.18%) | 45 (39.82%) | 1.000 |
 Squamous cell carcinoma | 101 | 60 (59.41%) | 41 (40.59%) |  |
TNM stage | ||||
 I–II | 138 | 91 (65.94%) | 47 (34.06%) | 0.019 |
 III | 76 | 37 (48.68%) | 39 (51.32%) |  |
Nodal status | ||||
 N0 | 137 | 98 (71.53%) | 39 (28.47%) |  < 0.0001 |
 N1, N2, N3 | 77 | 30 (38.96%) | 47 (61.04%) |  |
Differentiation | ||||
 Well-moderate | 118 | 68 (57.63%) | 50 (42.37%) | 0.487 |
 Poor | 96 | 60 (62.50%) | 36 (37.50%) |  |
Tumor size | ||||
 ≥ 3 cm | 126 | 68 (53.97%) | 58 (46.03%) | 0.037 |
 < 3 cm | 88 | 60 (68.18%) | 28 (31.82%) |  |